Treatment and Outcomes of Precocious Puberty: An Update
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Precocious puberty is a common problem affecting up to 29 per 100,000 girls per year. The earliest identified neuroendocrine change in early puberty thus far is increased kisspeptin secretion from the arcuate nucleus and the anteroventral paraventricular nucleus of the hypothalamus. The regulation of kisspeptin secretion is not well understood, but neurokinin B and dynorphin provide autocrine regulation. The etiologies of precocious puberty may be subdivided into GnRH-dependent and GnRH-independent causes. GnRH-dependent precocious puberty, often called central precocious puberty (CPP), is usually treated with GnRH analogs. Newer developments in the treatment of CPP include expanded data on the safety and efficacy of the subdermal histrelin implant, which is useful for long-term treatment, although removal may be difficult in some cases. Preliminary data suggest that the implant may be left in place for up to 2 years without loss of biochemical suppression. In the last 2 years, more data have been published concerning extended-release leuprolide acetate injections that indicate that the 11.25-mg dose may not provide full biochemical suppression but may clinically suppress signs of puberty, including the accelerated growth velocity and advanced skeletal maturation seen in CPP. Treatment options for familial male-limited precocious puberty and McCune-Albright syndrome are expanding as well, although data are preliminary. Long-term outcome studies of CPP indicate overall good menstrual and reproductive function, but the prevalence of polycystic ovary syndrome may be higher than in the general population. Remarkably few studies have evaluated the behavioral and psychological outcomes of precocious puberty, in contrast to early normal maturation. Additional outcome studies of endocrine, metabolic, and psychological effects of CPP are clearly needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Enlarged testis corresponding with the pubertal stage suggests GDPP, while pre-pubertal testis indicates GIPP.”
From Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty (2024) · cites this paper as [16]
In the citing paper
“Pubertal testis smaller than expected with pubic hair growth means apparent LH excess (hCG-secreting tumour or testotoxicosis) or GDPP superimposed on GIPP.16”
From Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty (2024) · cites this paper as [16]
In the citing paper
“The most important pointer to the source of androgen production in a boy with precocious puberty is testicular volume.”
From Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty (2024) · cites this paper as [16]
Citations
Cites
Variations in pattern of pubertal changes in girls
Marshall, W. A., & Tanner, J. M. (1969) · Archives of Disease in Childhood · doi:10.1136/adc.44.235.291 · Cited by 5,963 · cited 1×
“The degree of pubertal maturation is usually described using the Tanner stages of sexual maturation (4) (Table 1).”
MethodHerman-Giddens, M. E., Slora, E. J., Wasserman, R. C., Bourdony, C. J., Bhapkar, M. V., Koch, G. G., & Hasemeier, C. M. (1997) · PEDIATRICS · doi:10.1542/peds.99.4.505 · Cited by 1,709
Topaloglu, A. K., Reimann, F., Guclu, M., Yalin, A. S., Kotan, L. D., Porter, K. M., Serin, A., Mungan, N. O., Cook, J. R., Ozbek, M. N., et al. (2009) · Nature Genetics · doi:10.1038/ng.306 · Cited by 961 · cited 1×
“Although mutations of neurokinin b and dynorphin could theoretically cause early pubertal development, such mutations have not yet been identified (12).”
BackgroundConsensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children
Carel, J.-C., Eugster, E. A., Rogol, A., Ghizzoni, L., Palmert, M. R., & on behalf of the members of the ESPE-LWPES GnRH Analogs Consensus Conference Group (2009) · Pediatrics · doi:10.1542/peds.2008-1783 · Cited by 817 · cited 2×
“in those with CPP (30) than in those with normal puberty,”
BackgroundEarlier Onset of Puberty in Girls: Relation to Increased Body Mass Index and Race
Kaplowitz, P. B., Slora, E. J., Wasserman, R. C., Pedlow, S. E., & Herman-Giddens, M. E. (2001) · Pediatrics · doi:10.1542/peds.108.2.347 · Cited by 751
Wakabayashi, Y., Nakada, T., Murata, K., Ohkura, S., Mogi, K., Navarro, V. M., Clifton, D. K., Mori, Y., Tsukamura, H., Maeda, K.-I., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5848-09.2010 · Cited by 597 · cited 5×
“org J Clin Endocrinol Metab, June 2013, 98(6):2198–2207 doi: 10.”
BackgroundInfluentialA GPR54 -Activating Mutation in a Patient with Central Precocious Puberty
Teles, M. G., Bianco, S. D. C., Brito, V. N., Trarbach, E. B., Kuohung, W., Xu, S., Seminara, S. B., Mendonca, B. B., Kaiser, U. B., & Latronico, A. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073443 · Cited by 572 · cited 1×
“in individuals with precocious puberty (10, 11).”
Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index
Rosenfield, R. L., Lipton, R. B., & Drum, M. L. (2009) · PEDIATRICS · doi:10.1542/peds.2008-0146 · Cited by 499
Herman-Giddens, M. E., Steffes, J., Harris, D., Slora, E., Hussey, M., Dowshen, S. A., Wasserman, R., Serwint, J. R., Smitherman, L., & Reiter, E. O. (2012) · PEDIATRICS · doi:10.1542/peds.2011-3291 · Cited by 392
Sørensen, K., Mouritsen, A., Aksglaede, L., Hagen, C. P., Mogensen, S. S., & Juul, A. (2012) · Hormone Research in Paediatrics · doi:10.1159/000336325 · Cited by 386
Cited by
Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium
Bangalore Krishna, K., Fuqua, J. S., Rogol, A. D., Klein, K. O., Popovic, J., Houk, C. P., Charmandari, E., & Lee, P. A. (2019) · Hormone Research in Paediatrics · doi:10.1159/000501336 · Cited by 293
Self-citationGnRH and GnRH receptors in the pathophysiology of the human female reproductive system
Maggi, R., Cariboni, A. M., Marelli, M. M., Moretti, R. M., Andrè, V., Marzagalli, M., & Limonta, P. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmv059 · Cited by 269
“Recently it has also been proposed that neurokinin B and leptin may play an essential role in the activation of GnRH neurons and in the initiation of an increased LH pulse frequency under a PCOSlike androgen excess and that kisspeptin may coordinate their stimulatory effects on LH release (Yan et al., 2014).”
BackgroundInfluentialAdolescent Growth and Development
Chulani, V. L., & Gordon, L. P. (2014) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2014.05.002 · Cited by 186
Diagnosis and management of precocious sexual maturation: an updated review
Cheuiche, A. V., da Silveira, L. G., de Paula, L. C. P., Lucena, I. R. S., & Silveiro, S. P. (2021) · European Journal of Pediatrics · doi:10.1007/s00431-021-04022-1 · Cited by 183
Mental Health Concerns and Insurance Denials Among Transgender Adolescents
Nahata, L., Quinn, G. P., Caltabellotta, N. M., & Tishelman, A. C. (2017) · LGBT Health · doi:10.1089/lgbt.2016.0151 · Cited by 158
“Despite scant research documenting positive or negative psychosocial outcomes among youth with precocious puberty, they are still routinely granted insurance coverage for puberty blockers due to potential psychosocial concerns, whereas transgender youth are not.(26,34) With significantly more data documenting the psyc…”
Central Precocious Puberty: Update on Diagnosis and Treatment
Chen, M. E., & Eugster, E. A. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0130-8 · Cited by 160
“Currently, no consensus exists on whether CPP or treatment with GnRHa results in an increased risk of PCOS [2, 54, 56].”
BackgroundInfluentialCentral precocious puberty: revisiting the diagnosis and therapeutic management
Brito, V. N., Spinola‐Castro, A. M., Kochi, C., Kopacek, C., da Silva, P. C. A., & Guerra‐Júnior, G. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000144 · Cited by 151
“The treatment of CPP with GnRHa is monitored by clinical and laboratory evaluations (10,15).”
BackgroundMethodInfluentialCentral precocious puberty: a review of diagnosis, treatment, and outcomes
Zevin, E. L., & Eugster, E. A. (2023) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(23)00237-7 · Cited by 164
Central precocious puberty: From genetics to treatment
Aguirre, R. S., & Eugster, E. A. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.05.008 · Cited by 130
Puberty suppression in transgender children and adolescents
Mahfouda, S., Moore, J. K., Siafarikas, A., Zepf, F. D., & Lin, A. P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30099-2 · Cited by 133
Ramsey, J. T., Li, Y., Arao, Y., Naidu, A., Coons, L. A., Díaz, A., & Korach, K. S. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01880 · Cited by 108
“in girls and gonadarche is considered normal after age 9 years in boys (38).”
BackgroundMolecular insights into the aetiology of female reproductive ageing
Perry, J. R. B., Murray, A., Day, F. R., & Ong, K. K. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.167 · Cited by 87
Lazar, L., Meyerovitch, J., de Vries, L., Phillip, M., & Lebenthal, Y. (2013) · Clinical Endocrinology · doi:10.1111/cen.12319 · Cited by 83
Lazar, L., Lebenthal, Y., Yackobovitch‐Gavan, M., Shalitin, S., de Vries, L., Phillip, M., & Meyerovitch, J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3748 · Cited by 80
“Central precocious puberty (CPP) in girls, defined as the appearance of secondary sex characteristics before the age of 8 years due to premature activation of the hypothalamic-pituitary-gonadal axis, is considered idiopathic for most girls (1, 2).”
Puberty and its disorders in the female
Rosenfield, R. L., Cooke, D. W., & Radovick, S. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00024-x · Cited by 74
Sanctis, V. D., Soliman, A. T., Maio, S. D., Soliman, N., & Elsedfy, H. H. (2019) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v90i3.8736 · Cited by 76
“25 mg are the most common formulation used to treat CPP as they cause a steady release of the drug without relevant side effects (1-4,8).”
BackgroundInfluentialSilverman, L. A., Neely, E. K., Kletter, G. B., Lewis, K., Chitra, S., Terleckyj, O., & Eugster, E. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3031 · Cited by 62
Transgender medicine - puberty suppression
Panagiotakopoulos, L. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9457-0 · Cited by 66
Chemaitilly, W., Merchant, T. E., Li, Z., Barnes, N., Armstrong, G. T., Ness, K. K., Pui, C., Kun, L. E., Robison, L. L., Hudson, M. M., et al. (2016) · Clinical Endocrinology · doi:10.1111/cen.12964 · Cited by 62
Update on central precocious puberty: from etiologies to outcomes
Cantas-Orsdemir, S., & Eugster, E. A. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1575726 · Cited by 63
“Several genetic syndromes are also associated with CPP [3].”
BackgroundInfluentialLuo, X., Liang, Y., Hou, L., Wu, W., Ying, Y., & Ye, F. (2021) · Clinical Endocrinology · doi:10.1111/cen.14410 · Cited by 60
The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B
Patel, B., Koysombat, K., Mills, E., Tsoutsouki, J., Comninos, A. N., Abbara, A., & Dhillo, W. S. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad023 · Cited by 72
Assessing hypothalamic pituitary gonadal function in reproductive disorders
Koysombat, K., Dhillo, W. S., & Abbara, A. (2023) · Clinical Science · doi:10.1042/cs20220146 · Cited by 59
Varimo, T. J., Huttunen, H., Miettinen, P. J., Kariola, L., Hietamäki, J., Tarkkanen, A., Hero, M. T., & Raivio, T. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00213 · Cited by 48
Rahim, S. N. A., Omar, J., & Ismail, T. S. T. (2020) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2040004.002 · Cited by 45
Dutta, D., Kumar, M., & Mukhopadhyay, S. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.149316 · Cited by 50
“The earliest clinical sign suggestive of onset of puberty is breast enlargement (thelarche) in girls and increase in testicular volume in boys, with the entire process of maturation completing within 4 years of onset.[1,7,8] Kisspeptin produced by arcuate nucleus and anteroventral periventricular area of the hypothala…”
BackgroundMethodInfluentialSyndromic Disorders Caused by Disturbed Human Imprinting
Carli, D., Riberi, E., Ferrero, G. B., & Mussa, A. (2019) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2019.2018.0249 · Cited by 46
“000, with an overall male to female ratio of at least 1:10 [96].”
BackgroundExpert management of congenital portosystemic shunts and their complications
McLin, V. A., Franchi‐Abella, S., Brütsch, T., Bahadori, A., Casotti, V., de Goyet, J. D. V., Dumery, G., Gonzales, E. M., Guérin, F., Hascoët, S., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100933 · Cited by 56
“42,51 Testing for hyperandrogenism is recommended in both adults and children with CPSS. Conversely, CPSS may be considered in cases of unexplained hyperandrogenism, especially with a relatively high fraction of DHEA compared to DHEA-S.”
BackgroundYellapragada, V., Liu, X., Lund, C., Känsäkoski, J., Pulli, K., Vuoristo, S., Lundin, K., Tuuri, T., Varjosalo, M. T., & Raivio, T. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00048 · Cited by 45
“In girls, the annual incidence of CPP varied from 15 to 29 per 1,00,000 (5), and the overall risk and incidence is higher in girls than in boys (2, 3, 6).”
BackgroundTan, Y., Xu, X., Cao, H., Zhou, W., & Yin, Z. (2021) · Poultry Science · doi:10.1016/j.psj.2021.101325 · Cited by 45
“We could speculate that the EPR of the precocious individuals was low due to the abnormal ovulation function at early stage and such negative effects will affect the entire egg production cycle (Fuqua, 2013).”
BackgroundPuberty in Non-human Primates and Man
Plant, T. M., Terasawa, E., & Witchel, S. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397175-3.00032-6 · Cited by 43
Neely, E. K., & Crossen, S. S. (2014) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000099 · Cited by 41
Klein, K. O., Freire, A. V., Gryngarten, M. G., Kletter, G. B., Benson, M. R., Miller, B. S., Dajani, T., Eugster, E. A., & Mauras, N. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa479 · Cited by 42
“Optimal treatment inhibits the physical signs of pubertal progression, returns growth velocity to normal prepubertal rates, decreases the rate of bone maturation, improves predicted adult height, and suppresses pubertal hormonal measures (4-7).”
BackgroundPopovic, J., Geffner, M. E., Rogol, A. D., Silverman, L. A., Kaplowitz, P. B., Mauras, N., Zeitler, P. S., Eugster, E. A., & Klein, K. O. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.968485 · Cited by 35
“Children with central precocious puberty (CPP) exhibit puberty earlier as a result of premature activation of the hypothalamic-pituitarygonadal (HPG) axis (2).”
BackgroundFaienza, M. F., Brunetti, G., Acquafredda, A., Delvecchio, M., Lonero, A., Gaeta, A., Suavo-Bulzis, P., Corica, D., Velletri, M. R., Luca, F. D., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000456546 · Cited by 37
Yu, C., Liu, P., Van, Y.-H., Lien, A. S., Huang, T.-P., & Yen, H. (2014) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2014.01.002 · Cited by 35
Presentation of Congenital Portosystemic Shunts in Children
Bahadori, A., Kuhlmann, B., Debray, D., Franchi‐Abella, S., Wacker, J., Beghetti, M., Wildhaber, B. E., McLin, V. A., & IRCPSS, O. B. O. T. (2022) · Children · doi:10.3390/children9020243 · Cited by 45
“Hyperandrogenism by itself and over time leads to accelerated somatic maturation and bone age, which therefore causes central precocious puberty and early acceleration of growth velocity [72].”
BackgroundKisspeptin and neurokinin B: roles in reproductive health
Koysombat, K., Tsoutsouki, J., Patel, A., Comninos, A. N., Dhillo, W. S., & Abbara, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00015.2024 · Cited by 45
Precocious Puberty: Types, Pathogenesis and Updated Management
Alghamdi, A. (2023) · Cureus · doi:10.7759/cureus.47485 · Cited by 57
Janjic, M. M., Prévide, R. M., Fletcher, P. A., Sherman, A., Smiljanić, K., Abebe, D. T., Bjelobaba, I. M., & Stojilković, S. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-56480-1 · Cited by 31
Treatment Response in Pediatric Patients With Pseudotumor Cerebri Syndrome
Tovia, E., Reif, S. S., Oren, A., Mitelpunkt, A., & Fattal‐Valevski, A. (2017) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000516 · Cited by 28
Bertelloni, S., Massart, F., Einaudi, S., Wasniewska, M. G., Miccoli, M., & Baroncelli, G. I. (2015) · Hormone Research in Paediatrics · doi:10.1159/000441497 · Cited by 27
Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
Arani, K. S., & Heidari, F. (2015) · Intern J Endocrinol Metab · doi:10.5812/ijem.23085v2 · Cited by 31
“Depot preparations of gonadotropin-releasing hormone agonists (GnRHa) are the gold standard drugs for the treatment of rapidly progressive forms of CPP (4).”
BackgroundResumption of Puberty in Girls and Boys Following Removal of the Histrelin Implant
Fisher, M. M., Lemay, D., & Eugster, E. A. (2014) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.12.009 · Cited by 25
Current pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties
Bertelloni, S., & Baroncelli, G. I. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.806489 · Cited by 26
“The goals of treatment are to stop the premature sexual maturation and to prevent somatic and psychological problems related to the precocious pubertal development [1,12,13,22].”
BackgroundInfluentialDeWire, M. D., Green, D. M., Sklar, C. A., Merchant, T. E., Wallace, D., Lin, T., Vern-Gross, T. Z., Kun, L. E., Krasin, M. J., Boyett, J. M., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25274 · Cited by 25
“These contemporary secular trends have lead to debate about age of pubertal onset, yet age of menarche has not changed in the decades [29].”
BackgroundSaleh, F., & Taylor, H. S. (2023) · F&S Reports · doi:10.1016/j.xfre.2023.01.008 · Cited by 38
“Precocious puberty can be organized into 2 broad categories on the basis of the driving forces of early development: central and peripheral (29, 33).”
BackgroundPrinciplism and contemporary ethical considerations for providers of transgender health care
Allen, L. R., Adams, N., Ashley, F., Dodd, C. G., Ehrensaft, D., Fraser, L., Garcia, M. M., Giordano, S., Green, J., Johnson, T. W., et al. (2024) · International Journal of Transgender Health · doi:10.1080/26895269.2024.2303462 · Cited by 29
“Further restricting access to puberty blockers for transgender and gender-questioning youths may be contrary to the principle of justice since puberty blockers are widely available for central precocious puberty without an evaluation of gender identity (Fuqua, 2013).”
Pituitary gonadotroph-specific patterns of gene expression and hormone secretion
Constantin, S., Bjelobaba, I. M., & Stojilković, S. S. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102274 · Cited by 31
Zepf, F. D., König, L., Kaiser, A. M., Ligges, C., Ligges, M., Roessner, V., Banaschewski, T., & Holtmann, M. H. (2024) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000972 · Cited by 27
Paraneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms
Guilmette, J. M., & Nosé, V. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.03.002 · Cited by 27
Rossi, A., D’Arino, A., Pigliacelli, F., Caro, G., Muscianese, M., Fortuna, M. C., & Carlesimo, M. (2019) · Australasian Journal of Dermatology · doi:10.1111/ajd.13079 · Cited by 25
“by gonadal or extragonadal tissue independent of pituitary stimulation.(51) The occurrence of puberty at an earlier age than usual can justify the appearance of AGA in”
BackgroundThe association between vitamin D levels and precocious puberty: a meta-analysis
Liu, S., Zhu, X., Wang, Y., Yan, S., Li, D., & Cui, W. (2020) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0388 · Cited by 22
Precocious Puberty—Perspectives on Diagnosis and Management
Menon, P. S. N., & Vijayakumar, M. (2013) · The Indian Journal of Pediatrics · doi:10.1007/s12098-013-1177-6 · Cited by 20
“Histrelin implants (50 mg) are effective for one year [41, 42].”
BackgroundAgopiantz, M., Journeau, P., Lebon-Labich, B., Sorlin, A., Cuny, T., Weryha, G., & Leheup, B. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.01.002 · Cited by 21
Delayed and Precocious Puberty: Genetic Underpinnings and Treatments
Gohil, A., & Eugster, E. A. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.08.002 · Cited by 21
“Precocious Puberty Precocious puberty refers to secondary sexual development ensuing prior to the norms for racial or ethnic background and traditionally has been defined as prior to age 8 in girls and age 9 in boys [54,55].”
The Influence of GnRH Analog Therapy on Growth in Central Precocious Puberty
Głąb, E., Wikiera, B., Bieniasz, J., & Barg, E. (2015) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/31433 · Cited by 20
“Children with more advanced bone age may present greater deceleration of osseous maturation and growth velocity [6, 13].”
BackgroundHu, Z., Chen, R., & Cai, C. (2016) · Pediatric Research · doi:10.1038/pr.2016.107 · Cited by 22
Puberty in the Female and Its Disorders
Rosenfield, R. L., Cooke, D. W., & Radovick, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00016-6 · Cited by 36
Kisspeptin Levels in Girls with Precocious Puberty: A Systematic Review and Meta-Analysis
Cintra, R. G., Wajnsztejn, R., Trevisan, C. M., Zaia, V., Laganà, A. S., Bianco, B. A. V., & Montagna, E. (2020) · Hormone Research in Paediatrics · doi:10.1159/000515660 · Cited by 22
Lee, H.-K., Choi, S., Fan, D., Jang, K. M., Kim, M.-S., & Hwang, C. (2018) · The Angle Orthodontist · doi:10.2319/112317-809.1 · Cited by 19
“The incidence of precocious puberty is 10- to 15-fold higher in girls than boys, and the annual incidence in girls is 15–29 per 100,000 girls over an 8-year period.(2)”
BackgroundNonneuroendocrine Neoplasms of the Pituitary Region
Kaltsas, G., Kolomodi, D., Randeva, H. S., & Grossman, A. B. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01871 · Cited by 22
Cho, A. Y., Shim, Y. S., Lee, H. S., & Hwang, J. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-28602-3 · Cited by 18
Glatstein, M. M., Oren, A., Amarilyio, G., Scolnik, D., Ben‐Tov, A., Yahav, A., Alper, A., & Reif, S. S. (2014) · Pediatric Emergency Care · doi:10.1097/pec.0000000000000177 · Cited by 18
“We defined prepubertal children as those younger than 11 years and pubertal patients as those with age between 11 and 17 years or older because, by the age of 11 years, most children have begun puberty.(12)”
MethodGangat, M., & Radovick, S. (2021) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05970-8 · Cited by 24
Lin, W.-D., Wang, C., & Tsai, F. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0408 · Cited by 21
GnRHa/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty
Zhu, S., Long, L., Hu, Y., Tuo, Y., Li, Y., & Yu, Z. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.678797 · Cited by 17
The impact of legislation on drug substances used off-label in paediatric wards—a nationwide study
Haslund‐Krog, S. S., Mathiasen, R., Christensen, H. R., & Holst, H. D. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1626-1 · Cited by 17
Sinthuprasith, P., Dejkhamron, P., Wejaphikul, K., & Unachak, K. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0136 · Cited by 17
Vuković, R., Milenković, T., Soldatović, I., Pekić, S., Mitrović, K., & Todorovic, S. (2021) · Endocrine · doi:10.1007/s12020-021-02947-z · Cited by 19
Gonadotropin-Releasing Hormone Agonist Treatment in Sexual Precocity
Pienkowski, C., & Tauber, M. (2015) · Endocrine development · doi:10.1159/000438893 · Cited by 17
Stecchini, M. F., Braid, Z., More, C. B., Aragon, D. C., de Castro, M., Moreira, A. C., & Antonini, S. R. R. (2019) · Endocrine Connections · doi:10.1530/ec-19-0141 · Cited by 17
Loochi, S. A., Demol, S., Nagelberg, N., Lebenthal, Y., Phillip, M., & Yackobovitch‐Gavan, M. (2021) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2020-0471 · Cited by 18
Histrelin implantation in the pediatric population: A 10-year institutional experience
Swendiman, R. A., Vogiatzi, M. G., Alter, C. A., & Nance, M. L. (2018) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2018.08.048 · Cited by 16
Song, W., Zhao, F., Liang, S., Li, G., & Xue, J. (2018) · International Journal of Endocrinology · doi:10.1155/2018/1708650 · Cited by 16
“Idiopathic central precocious puberty leads to a short final stature compared with the PAH or target height, as does early puberty with advanced BA [28].”
BackgroundYüce, Ö., Bıdecı, A., Çelik, N., Camurdan, O. M., & Cınaz, P. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000212 · Cited by 16
“The treatment’s effectiveness was evaluated every 3-4 months, based on a set of clinical and hormonal data, such as regression or arrest pubertal progression, decrease in growth velocity, reduction of bone age advancement, and improvement in final height prediction (16).”
MethodCho, A. Y., Ko, S. Y., Lee, J. H., & Kim, E. Y. (2021) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2040268.134 · Cited by 16
Experience with the Histrelin Implant in Pediatric Patients
Eugster, E. A. (2015) · Endocrine development · doi:10.1159/000439330 · Cited by 15
Hansen, A. B., Wøjdemann, D., Renault, C. H., Pedersen, A. T., Main, K. M., Rakêt, L. L., Jensen, R. B., & Juul, A. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0545 · Cited by 21
Central Precocious Puberty and Psychiatric Disorders
Dinkelbach, L., Grasemann, C., Kiewert, C., Leikeim, L., Schmidt, B., & Hirtz, R. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.16679 · Cited by 23
Ramos, C. O., Canton, A. P. M., Seraphim, C. E., de Faria, A. G., Tinano, F. R., Mendonca, B. B., Latronico, A. C., & Brito, V. N. (2021) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2021-0142 · Cited by 16
Diagnosis and management of pituitary adenomas in children and adolescents
Maiter, D. M., Chanson, P., Constantinescu, S. M., & Linglart, A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae120 · Cited by 20
Hyperplasia in glands with hormone excess
Marx, S. J. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0171 · Cited by 16
“2010, Fuqua 2013).”
Vitamin D status of school children in and around Guwahati
Sarma, D., Saikia, U., & Baro, A. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_552_18 · Cited by 15
“Puberty was assessed using the Tanner’s classification.[5] Fasting blood samples were taken for serum 25-hydroxy vitamin D [25(OH)D], serum calcium (Ca), albumin, phosphorus, alkaline phosphatase and intact parathyroid hormone (PTH).”
MethodEarly and late endocrine effects in pediatric central nervous system diseases
Aslan, I. R., & Cheung, C. C. (2014) · Journal of Pediatric Rehabilitation Medicine · doi:10.3233/prm-140299 · Cited by 16
“Children with precocious puberty should be treated with GnRH analogs, which provide a sustained rather than a pulsatile level of GnRH that is normal in puberty and post-puberty [59].”
Long, D. N. (2015) · Pediatrics in Review · doi:10.1542/pir.36-7-319 · Cited by 16
Wu, V., Zhao, V., Issa, R., Wilkes, M. A., Wallach, E., Rapaport, R., Romero, C. J., & Yau, M. (2021) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2040220.110 · Cited by 13
Clinical guidelines «Precocious puberty»
Peterkova, V. A., Алимова, И. Л., Bashnina, E. B., Bezlepkina, O. B., Bolotova, N. V., Zubkova, N. A., Kalinchenko, N. Y., Kareva, M., Kiyaev, A. V., Kolodkina, A. A., et al. (2021) · Problems of Endocrinology · doi:10.14341/probl12821 · Cited by 26
New insights into precocious puberty and ADHD: a nationwide cohort study
Pai, L.-F., Wang, D.-S., Hsu, W.-F., Huang, S.-W., Chung, C., Chen, S., Chien, W., & Chu, D. (2022) · Pediatric Research · doi:10.1038/s41390-022-02028-5 · Cited by 15
Association between MKRN3 and LIN28B polymorphisms and precocious puberty
Yi, B. R., Kim, H. J., Park, H., Cho, Y. J., Kim, J. Y., Yee, J., Chung, J. E., Kim, J. H., Lee, K. E., & Gwak, H. S. (2018) · BMC Genetics · doi:10.1186/s12863-018-0658-z · Cited by 13
Ramos, C. D. O., Macedo, D. B., Bachega, T. A. S. S., Nascimento, M. L., Madureira, G., Latronico, A. C., Brito, V. N., & Mendonca, B. B. (2019) · Hormone Research in Paediatrics · doi:10.1159/000495664 · Cited by 13
Elchuri, S. V., & Momen, J. (2020) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2020.02.001 · Cited by 14
Wang, S., Zhu, L., Yu, J., & Tian, Z. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/217424 · Cited by 13
Ma, Y., Sun, F., Zhang, E., Li, J., Yue, S., Fu, Y., & Zhang, S. (2023) · Medicine · doi:10.1097/md.0000000000036395 · Cited by 14
“[1,11,12] Traditional Chinese medicine (TCM) is widely used to treat precocious puberty in clinic.”
BackgroundNahata, L., Chelvakumar, G., & Leibowitz, S. F. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017718845 · Cited by 12
“Long-term studies in this population show that GnRH analogues are effective, reversible, and safe.(17) Short-term follow-up studies after pubertal suppression in Dutch youth with gender dysphoria show no adverse events, along with an improvement in psychological functioning and a decrease in depressive symptoms, and b…”
BackgroundBreast diseases in children: the spectrum of radiologic findings in a cohort study
Durmaz, E., Öztek, M. A., Habibi, H. A., Kesimal, U., & Sindel, T. (2017) · Diagnostic and Interventional Radiology · doi:10.5152/dir.2017.17033 · Cited by 12
Park, S. C., Trinh, T. A., Lee, W.-Y., Baek, J. Y., Lee, S. Y., Choi, K. H., Ha, J., Kim, C.-E., Kang, K. S., & Lee, H. L. (2020) · Integrative Medicine Research · doi:10.1016/j.imr.2020.100708 · Cited by 12
Katić, L., & Priscan, A. (2023) · Biomolecules · doi:10.3390/biom13101490 · Cited by 11
“Puberty delay might be beneficial for patients with precox puberty, which is becoming a growing concern [120].”
BackgroundHuang, X.-Y., Chen, J.-X., Ren, Y., Luo, H., Xiang, W., He, X., & Li, T. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149199 · Cited by 12
A dual kisspeptin-GnRH immunogen for reproductive immunosterilization
Junco, J. A., Fuentes, F., & Millar, R. P. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.080 · Cited by 14
Metadata
- Authors
- Fuqua, J. S.
- Affiliations
- Indiana University Indianapolis (US)
- Corresponding author
- Fuqua, John S.
- ORCID
- Fuqua, John S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-06-01
- Volume
- 98
- Issue
- 6
- Pages
- 2198-2207
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2170468182
- Cited by
- 260
- References
- 61
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 20 · 2023: 27 · 2022: 17 · 2021: 23 · 2020: 21 · 2019: 23 · 2018: 12 · 2017: 22 · 2016: 13 · 2015: 31 · 2014: 20 · 2013: 4
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- precocious puberty, central precocious puberty, GnRH analogues, kisspeptin, neurokinin B, dynorphin, leuprolide, familial male-limited precocious puberty, McCune-Albright syndrome, polycystic ovary syndrome, skeletal maturation, psychological outcomes, treatment outcomes
- MeSH terms
- Delayed-Action Preparations, Drug Implants, Female, Humans, Gonadotropin-Releasing Hormone, Male, Puberty, Puberty, Precocious, Leuprolide, Treatment Outcome, Kisspeptins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.